Skip to main content

Table 1 Overview of drug collection

From: Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Drug class Approved Investigational (Phase I-III) Preclinical Total
Conventional chemotherapy 58 5 3 66
Kinase inhibitor 32 172 26 230
Rapalog 4 1 0 5
Immunomodulatory 10 3 0 13
Differentiating/epigenetic modifier 10 21 20 51
Hormone therapy 18 3 1 22
Apoptotic modulator 0 12 3 15
Metabolic modifier 8 5 4 17
Kinesin inhibitor 0 3 0 3
NSAID 2 0 0 2
Heat shock protein inhibitor 0 6 2 8
Proteasome inhibitor 2 1 1 4
Hedgehog inhibitor 1 1 0 2
Other 7 8 8 23
Total number
(% of total)
152 (33%) 241 (52%) 68 (15%) 461